Top Markets
Coin of the day
Fusion Antibodies plc Fusion Antibodies plc

Fusion Antibodies plc

FAB
Rang in aandelen #20442
Fusion Antibodies plc, a contract research organization, engages in the... Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. It offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services. The company serves pharmaceutical, biotech, and diagnostic companies. It has a collaboration partnership with Celonic AG. Fusion Antibodies plc was incorporated in 2000 and is headquartered in Belfast, the United Kingdom.
Aandeelprijs
$0.16328419
Marktkapitalisatie
$204.14K
Verandering (1 dag)
4.35%
Verandering (1 jaar)
102.45%
Land
GB
Handel Fusion Antibodies plc (FAB)

Categorie

Winst voor Fusion Antibodies plc (FAB)
Winst in Sep 2025 TTM: $-2.06M
Volgens de meest recente financiële verslagen van Fusion Antibodies plc bedraagt de huidige winst van het bedrijf $-2.06M. In 2024 behaalde het bedrijf een winst van $-2.89M, een stijging ten opzichte van de winst van 2023, die $-3.53M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Fusion Antibodies plc van 2013 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $-2.06M -10.23%
2025 $-2.30M -20.56%
2024 $-2.89M -18.12%
2023 $-3.53M 101.40%
2022 $-1.75M 0.58%
2021 $-1.74M 30.88%
2020 $-1.33M -31.84%
2019 $-1.95M 95.89%
2018 $-997.05K -731.20%
2017 $157.96K 304.33%
2016 $39.07K -126.49%
2015 $-147.46K -26.55%
2014 $-200.78K -72.11%
2013 $-719.78K 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$20.46B -992,770.77%
DK
$4.64B -225,408.48%
US
$5.23B -253,916.57%
US
$2.14B -103,830.35%
BE
$1.45B -70,512.80%
NL